Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

• Published in: World journal of gastroenterology : WJG 2015-07, Vol.21 (26), p.8140-8147
• Main Authors: Al-Hamoudi, Waleed, Elsiesy, Hussien, Bendahmash, Abdulrahman, Al-Masri, Nasser, Ali, Safiyya, Allam, Naglaa, Al Sofayan, Mohammed, Al Bahili, Hamad, Al Sebayel, Mohammed, Broering, Dieter, Saab, Sammy, Abaalkhail, Faisal
• Format: Article
• Language: English
• Subjects: Adult; Antiviral Agents - therapeutic use; Biomarkers - blood; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - surgery; Carcinoma, Hepatocellular - virology; Disease Progression; Female; Hepatitis B - complications; Hepatitis B - diagnosis; Hepatitis B - drug therapy; Hepatitis B - mortality; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B virus - immunology; Humans; Liver Cirrhosis - diagnosis; Liver Cirrhosis - mortality; Liver Cirrhosis - surgery; Liver Cirrhosis - virology; Liver Neoplasms - diagnosis; Liver Neoplasms - mortality; Liver Neoplasms - surgery; Liver Neoplasms - virology; Liver Transplantation - adverse effects; Liver Transplantation - mortality; Liver Transplantation - trends; Male; Middle Aged; Recurrence; Retrospective Studies; Retrospective Study; Risk Factors; Saudi Arabia; Time Factors; Treatment Outcome; Viral Load; Virus Activation
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v21.i26.8140

To evaluate the indication and outcome of hepatitis B virus (HBV)-related liver transplantation (LT) in the era of newer antiviral agents. We collected data on all patients who underwent transplantation at King Faisal Specialist Hospital and Research Center. These data included demographic, perioperative and long-term postoperative follow-up data including viral serological markers, HBV DNA, and repeated liver imaging. Between January 1990 and January 2012, 133 patients (106 males and 27 females) underwent LT for HBV-related cirrhosis at our center. All patients were followed up frequently during the first year following transplantation, according to our standard protocol; follow-up visits occurred every 3-6 mo thereafter. Breakthrough infection was defined as re-emergence of HBV-DNA or hepatitis B surface antigen (HBsAg) while on treatment. Five patients transplanted prior to 1992 did not receive immediate posttransplant anti-HBV prophylaxis; all other patients were treated with HBIG and at least one nucleos(t)ide analog. One hundred and thirty-three patients underwent LT for HBV and were followed for a median of 82 mo (range: 1-274). The rates of post-LT survival and HBV recurrence during the follow-up period were 89% and 11%, respectively. The following factors were associated with disease recurrence: younger age (44.3 ± 16.2 years vs 51.4 ± 9.9 years, P = 0.02), positive pretransplant hepatitis B e antigen (HBeAg) (60% vs 14%, P < 0.0001), detectable pretransplant HBV DNA (60% vs 27%, P = 0.03), positive posttransplant HBsAg (80% vs 4%, P < 0.0001) and positive posttransplant HBeAg (27% vs 1%, P < 0.0001). Forty-four (33%) patients had hepatocellular carcinoma (HCC). In the first (pre-2007) group, HBV was the second leading indication for LT after hepatitis C virus infection. A total of 64 transplants were performed, including 46 (72%) for decompensated HBV cirrhosis, 12 (19%) for decompensated cirrhosis complicated by HCC and 6 (10%) for compensated cirrhosis complicated by HCC. In the second group, nonalcoholic steatohepatitis surpassed HBV as the second leading indication for LT. A total of 69 HBV related transplants were performed, including 43 (62%) for decompensated HBV cirrhosis, 7 (10%) for decompensated cirrhosis complicated by HCC and 19 (27.5%) for compensated cirrhosis complicated by HCC. There was a significant (P = 0.007) increase in the number of transplants for compensated cirrhosis complicated by HCC. The use of potent anti-HBV agents